AE

Ameena El-bibany

Investor

San Francisco Bay Area

Overview 

Ameena El-Bibany is a seasoned early-stage investor in tech and bio, currently serving as a Partner at ARTIS Ventures and Rising Tide VC. She has made significant investments in companies like Range Biotechnologies and Activ Surgical, contributing to their growth and success in the digital health and biotech sectors. With a background in synthetic biology and technology commercialization, Ameena has played key roles in various companies as an investor and board member, demonstrating a strong track record in identifying promising startups and providing strategic guidance for their development.

Work Experience 

  • Seed Investor

    2021 - Current

Inceptive designs RNA molecules using large-scale deep learning in a tight loop with high-throughput experiments.

Raised $120,000,000.00 from Obvious Ventures, NVIDIA, Section 32 and Andreessen Horowitz.

  • Investor and Board Member

    2023

Range Biotechnologies is creating tools to enable personalized health through translational proteomics.

Raised $5,200,000.00 from Hawktail Management, Pear VC, Civilization Ventures, Artis Ventures (AV), Page One Ventures, Pillar VC and Four Cities Capital.

  • Investor and Board Member

    2020

Activ Surgical is a digital surgery company focused on improving surgical efficiency, accuracy, patient outcomes, and accessibility.

Raised $100,400,038.00 from Ronovo Surgical, Mint Venture Partners, Tao Capital Partners, Cota Capital, ATEL Growth Capital, LRVHealth, Alumni Ventures, Rising Tide, Magnetar Capital and Hikma Ventures.

  • Partner

    2019 - 2024

ARTIS Ventures is a venture capital firm that invests in category defining companies in TechBio, the intersection of technology and biology.

  • Partner

    2014 - 2019

    Exits: Precision NanoSystems (acquired by Danaher) Apama Medical (acquired by Boston Scientific) Loop Genomics (acquired by Element Bio) Active Investments: Exo (RA Capital, BlackRock, BOLD, Applied Ventures, Intel, Action Potential VC) Evonetix (Foresite Capital, DCVC, Draper Esprit) GRO Biosciences (Leaps by Bayer, Redmile, Innovation Endeavors) Volta Labs (Maverick Ventures, Khosla Ventures, Casdin) Activ Surgical (GreatPoint Ventures, 8VC) Aspect Biosystems (Radical, Pangaea Ventures) Unnatural Products (ARTIS Ventures)

Rising Tide is a Venture Capital Firm.

  • Stem Cell Research Assistant

    2012 - 2013

    • Tested conditions for optimal induction and stabilization of equine induced pluripotent stem cells (iPSCs). • Independently conducted secondary immunofluorescence staining of Oct-4 and CDX2 genes in equine inner cell mass and bovine embryos; collected data using a fluorescence microscope. • Cultured and passaged equine fibroblast and Chinese hamster ovary (CHO) cell lines in sterile conditions.

  • Microbiome Data Analyst

    2013 - 2013

    • Analyzed large metagenomic dataset of gut microbiota present in avian species from Papua New Guinea. • Calculated Shannon Indices and conducted Principal Component Analyses to compare gut bacterial diversity and composition, respectively, between sexes and among individuals of differing diet types. • Presented at the Society for Integrative and Comparative Biology National Conference, Austin, Texas, January 2014 — and — at the California Academy of Sciences, San Francisco, California, August 2013. Research Experience for Undergraduates Grant funded by the Robert T. Wallace Endowment for Undergraduate Research.

  • DNA Repair Researcher

    2013 - 2013

    • Discovered interspecific differences in both genotoxic susceptibility and DNA repair capacity in coelomocytes of echinoderm species with varying lifespans and a lack of decline in DNA repair capacity with age (contrary to mammals). • Quantified DNA strand break levels via Fast Micromethod Assay following acute exposure to UV-C or hydrogen peroxide. • Presented at the Bermuda Institute of Ocean Sciences, St. George’s, Bermuda, November 2013. Research Experience for Undergraduates Grant funded by the National Science Foundation.

  • Research and Development Scientist

    2012 - 2012

    • Demonstrated a 25% improved yield of targeted DNA extraction through new method compared to standard company procedure, while maintaining near-100% removal of undesired drug markers. • Designed and constructed plasmids through subcloning. Detected presence and quantified amount remaining ampicillin marker by Southern blot and dot blot, respectively. • Presented at Novozymes, Inc., Davis, California, September 2012.

Articles About Ameena

Relevant Websites